Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
Edouard L FuElisabetta PatornoBrendan M EverettMuthiah VaduganathanScott D SolomonRaisa LevinSebastian G SchneeweissRishi J DesaiPublished in: European heart journal (2023)
In routine US clinical practice, SGLT2i demonstrated robust clinical effectiveness in older adults with HF and type 2 diabetes compared with sitagliptin, with no evidence of heterogeneity across the SGLT2i class or across ejection fraction.
Keyphrases
- type diabetes
- ejection fraction
- clinical practice
- heart failure
- aortic stenosis
- glycemic control
- cardiovascular disease
- randomized controlled trial
- acute heart failure
- insulin resistance
- systematic review
- single cell
- physical activity
- atrial fibrillation
- left ventricular
- community dwelling
- cardiac resynchronization therapy